scholarly journals Correction: Text Messaging Versus Email Messaging to Support Patients With Major Depressive Disorder: Protocol for a Randomized Hybrid Type II Effectiveness-Implementation Trial

10.2196/34515 ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. e34515
Author(s):  
Medard Kofi Adu ◽  
Reham Shalaby ◽  
Ejemai Eboreime ◽  
Adegboyega Sapara ◽  
Nnamdi Nkire ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Text Messaging ◽  
Type Ii ◽  
Major Depressive ◽  
Hybrid Type ◽  
Implementation Trial

CORRECTION: "Text Messaging Versus Email Messaging to Support Patients With Major Depressive Disorder: Protocol for a Randomized Hybrid Type II Effectiveness-Implementation Trial" (Preprint)

2021 ◽  
Author(s):  
Vincent Agyapong ◽  
Medard Adu ◽  
Reham Shalaby ◽  
Ejemai Eboreime ◽  
Adegboyega Sapara ◽  
...  
Keyword(s):  
Mental Health ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Text Messaging ◽  
World Health ◽  
Depression Symptoms ◽  
Type Ii ◽  
Major Depressive ◽  
Hybrid Type ◽  
Study Results

BACKGROUND Background: Major depressive disorder (MDD) accounts for 40.5% of disability-adjusted life-years caused by mental and substance use disorders. Barriers such as stigma and financial and physical access to care have been reported, highlighting the need for innovative, accessible, and cost-effective psychological interventions. The effectiveness of supportive SMS text messaging in alleviating depression symptoms has been proven in clinical trials, but this approach can only help those with mobile phones. OBJECTIVE Objective: This paper presents the protocol for a study that will aim to evaluate the feasibility, comparative effectiveness, and user satisfaction of daily supportive email messaging as an effective strategy compared to daily supportive text messaging as part of the treatment of patients with MDD. METHODS Methods: This trial will be carried out using a hybrid type II implementation-effectiveness design. This design evaluates the effectiveness of an implementation strategy or intervention, while also evaluating the implementation context associated with the intervention. Patients with MDD receiving usual care will be randomized to receive either daily supportive email messaging or daily supportive text messaging of the same content for 6 months. The Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7 and the 5-item World Health Organization Well-Being Index will be used to evaluate the effectiveness of both strategies. The implementation evaluation will be guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework, as well as the Consolidated Framework for Implementation Research. All outcome measures will be analyzed using descriptive and inferential statistics. Qualitative data will be analyzed using thematic analysis. RESULTS Results: Data collection for this trial began in April 2021. We expect the study results to be available within 18 months of study commencement. The results will shed light on the feasibility, acceptability, and effectiveness of using automated emails as a strategy for delivering supportive messages to patients with MDD in comparison to text messaging. CONCLUSIONS Conclusions: The outcome of this trial will have a translational impact on routine patient care and access to mental health, as well as potential support mental health policy decision-making for health care resource allocation CLINICALTRIAL Trial Registration: ClinicalTrials.gov NCT04638231; https://clinicaltrials.gov/ct2/show/NCT04638231 International Registered Report Identifier (IRRID): DERR1-10.2196/29495

scholarly journals Text Messaging Versus Email Messaging to Support Patients With Major Depressive Disorder: Protocol for a Randomized Hybrid Type II Effectiveness-Implementation Trial

10.2196/29495 ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. e29495
Author(s):  
Medard Kofi Adu ◽  
Reham Shalaby ◽  
Ejemai Eboreime ◽  
Adegboyega Sapara ◽  
Nnamdi Nkire ◽  
...  
Keyword(s):  
Mental Health ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Text Messaging ◽  
World Health ◽  
Depression Symptoms ◽  
Type Ii ◽  
Major Depressive ◽  
Hybrid Type ◽  
Study Results

Background Major depressive disorder (MDD) accounts for 40.5% of disability-adjusted life years caused by mental and substance use disorders. Barriers such as stigma and financial and physical access to care have been reported, highlighting the need for innovative, accessible, and cost-effective psychological interventions. The effectiveness of supportive SMS text messaging in alleviating depression symptoms has been proven in clinical trials, but this approach can only help those with mobile phones. Objective This paper presents the protocol for a study that will aim to evaluate the feasibility, comparative effectiveness, and user satisfaction of daily supportive email messaging as an effective strategy compared to daily supportive text messaging as part of the treatment of patients with MDD. Methods This trial will be carried out using a hybrid type II implementation-effectiveness design. This design evaluates the effectiveness of an implementation strategy or intervention, while also evaluating the implementation context associated with the intervention. Patients with MDD receiving usual care will be randomized to receive either daily supportive email messaging or daily supportive text messaging of the same content for 6 months. The Patient Health Questionnaire-9, the Generalized Anxiety Disorder-7, and the 5-item World Health Organization Well-Being Index will be used to evaluate the effectiveness of both strategies. The implementation evaluation will be guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework, as well as the Consolidated Framework for Implementation Research. All outcome measures will be analyzed using descriptive and inferential statistics. Qualitative data will be analyzed using thematic analysis. Results Data collection for this trial began in April 2021. We expect the study results to be available within 18 months of study commencement. The results will shed light on the feasibility, acceptability, and effectiveness of using automated emails as a strategy for delivering supportive messages to patients with MDD in comparison to text messaging. Conclusions The outcome of this trial will have translational impact on routine patient care and access to mental health, as well as potentially support mental health policy decision-making for health care resource allocation. Trial Registration ClinicalTrials.gov NCT04638231; https://clinicaltrials.gov/ct2/show/NCT04638231 International Registered Report Identifier (IRRID) DERR1-10.2196/29495

scholarly journals Supportive Text Messaging versus Supportive E-mail Messaging for Patients with Major Depressive Disorder: Randomized Hybrid Type II Effectiveness-Implementation Trial Protocol (Preprint)

2021 ◽  
Author(s):  
Medard Adu ◽  
Reham Shalaby ◽  
Ejemai Eboreime ◽  
Adegboyega Sapara ◽  
Nnamdi Nkire ◽  
...  
Keyword(s):  
Mental Health ◽  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Text Messaging ◽  
Depression Symptoms ◽  
Type Ii ◽  
Major Depressive ◽  
Study Results ◽  
Supportive Messages ◽  
E Mail

BACKGROUND Major Depressive Disorder (MDD) accounts for 40·5% of disability-adjusted life years caused by mental and substance use disorders. Barriers such as stigma, financial and physical access to care have been reported, highlighting need for innovative, accessible and cost-effective psychological interventions. The effectiveness of supportive text messaging in alleviating depression symptoms has been proven in clinical trials, but this approach can only those with active cell phones. Consequently, this study seeks to evaluate the feasibility, comparative effectiveness, and user satisfaction of daily supportive daily e-mail messaging as an effective strategy compared to daily supportive text messaging, as part of treatment of patients with MDD. OBJECTIVE The Supportive Text versus Email Messaging (STEM) trial aims to evaluate comparatively the implementation and impact of two implementation strategies (text messaging and email messaging) for delivering supportive messages to patients with MDD. METHODS This trial will be carried out using a type II implementation-effectiveness hybrid trial. This design evaluates the effectiveness of an implementation strategy or intervention, while also evaluating the implementation context associated with the intervention. In this innovative pilot trial, patients with MDD receiving usual care will be randomized to receive either daily supportive email messaging or daily supportive text messaging of the same content for six months. The Patient Health Questionnaire (PHQ)-9 scale, the Generalized Anxiety Disorder (GAD)-7 scale and the WHO (Five) Well-Being Index will be used to evaluate the effectiveness of both strategies. Implementation evaluation will be guided by the Reach-Effectiveness-Adoption-Implementation-Maintenance (RE_AIM) framework, as well as the Consolidated Framework for Implementation Research (CFIR). All outcome measures will be analyzed using descriptive and inferential statistics. Qualitative data will be analyzed using thematic analysis. RESULTS Data collection for this trial began in April 2021. We expect the study results to be available within 18 months of study commencement. The study results will shed light on the feasibility, acceptability and effectiveness of using automated emails as a strategy for delivering supportive messages to patients with MDD, in comparison to text messaging. CONCLUSIONS The outcome of this trial will have translational impact on routine patient care, access to mental health as well as potentially support mental health policy decision making for healthcare resource allocation. CLINICALTRIAL ClinicalTrials.gov Identifier: NCT04638231

scholarly journals Regional Parieto-occipital Hypoperfusion on Arterial Spin Labeling Associates with Major Depressive Disorder

2020 ◽  
Vol 13 (1) ◽  
pp. 30-36
Author(s):  
Shingo Kihira ◽  
Clara Koo ◽  
Kambiz Nael ◽  
Puneet Belani
Keyword(s):  
Major Depressive Disorder ◽  
Depressive Disorder ◽  
Arterial Spin Labeling ◽  
Type Ii ◽  
Major Depressive ◽  
Age And Gender ◽  
Diabetes Mellitus Type Ii ◽  
Artery Disease ◽  
And Gender ◽  
Occipital Lobes

Background: Reduced cerebral blood flow in parieto-occipital regions has been reported in neurodegenerative disorders using ASL. We aimed to investigate neuropsychiatric and neurodegenerative comorbidities that may associate with parieto-occipital region hypoperfusion. Methods: This was a retrospective single-center study. Between March 2017 to May 2018, adult patients who underwent brain MRI with the inclusion of ASL perfusion and who had bilateral reductions of CBF in the parieto-occipital regions were included. ASL was performed using a pseudo-continuous arterial spin labeling (pCASL) technique on 1.5T MR system. Age and gender-matched patients with no perfusion defect were concurrently collected. Comorbidity data was collected from EMR, including major depressive disorder, Alzheimer’s disease, Parkinson’s disease, Schizophrenia, anxiety disorder, hypertension, diabetes mellitus type II, coronary artery disease, and chronic kidney disease. A Pearson’s Chi-Square test was performed to assess for comorbidities associated with hypoperfusion of the parieto-occipital lobes. Results: Our patient cohort consisted of 93 patients with bilateral hypoperfusion in the parieto-occipital lobes and 93 age and gender-matched patients without corresponding perfusion defects based on ASL-CBF. Among the comorbidities assessed, there was a statistically significant association between hypoperfusion of the parieto-occipital lobes and major depressive disorder (p=0.004) and Parkinson’s disease (p=0.044). There was no statistically significant association for Alzheimer’s disease, generalized anxiety disorder, diabetes mellitus type II, hypertension, coronary artery disease, or chronic kidney disease. Conclusion: Major depressive disorder may be linked to regional parieto-occipital hypoperfusion on ASL.

scholarly journals Possible Inhibitor from Traditional Chinese Medicine for theβForm of Calcium-Dependent Protein Kinase Type II in the Treatment of Major Depressive Disorder

2014 ◽  
Vol 2014 ◽  
pp. 1-14
Author(s):  
Tzu-Chieh Hung ◽  
Wen-Yuan Lee ◽  
Kuen-Bao Chen ◽  
Hung-Jin Huang ◽  
Yueh-Chiu Chan ◽  
...  
Keyword(s):  
Major Depressive Disorder ◽  
Chinese Medicine ◽  
Protein Kinase ◽  
Traditional Chinese Medicine ◽  
Depressive Disorder ◽  
Type Ii ◽  
Major Depressive ◽  
Dependent Protein Kinase ◽  
Structure Variation ◽  
Dependent Protein

Recently, an important topic of major depressive disorder (MDD) had been published in 2013. MDD is one of the most prevalent and disabling mental disorders. Consequently, much research is being undertaken into the causes and treatment. It has been found that inhibition of theβform of calcium/calmodulin-dependent protein kinase type II (β-CaMKII) can ameliorate the disorder. Upon screening the traditional Chinese medicine (TCM) database by molecular docking, sengesterone, labiatic acid, and methyl 3-O-feruloylquinate were selected for molecular dynamics. After 20 ns simulation, the RMSD, total energy, and structure variation could define the protein-ligand interaction. Furthermore, sengesterone, the principle candidate compound, has been found to have an effect on the regulation of emotions and memory development. In structure variation, we find the sample functional group of important amino acids make the protein stable and have limited variation. Due to similarity of structure variations, we suggest that these compounds may have an effect onβ-CaMKII and that sengesterone may have a similar efficacy as the control. However labiatic acid may be a stronger inhibitor ofβ-CaMKII based on the larger RMSD and variation.

Sign in / Sign up

Export Citation Format

Share Document